September 10, 2019
Intellectual Property and Bioprospecting: A Model Legal Framework
Society has long enjoyed the benefits of medical advances. In numerous cases, the biotechnology and pharmaceutical (biopharmaceutical) industries build on knowledge accumulated over centuries by traditional communities. As in the case of aspirin and morphine, the use of this knowledge has reduced the time and cost it takes to develop new drugs. Despite the community’s contribution, the law only provides rights to the person or firm that produces a medical product or service at the end of the process of discovery. Information about the knowledge that allowed these medical advancements to develop rarely comes to the forefront, and this creates tension between source communities and pharmaceutical companies. The controversy surrounding the involvement of Pfizer and Unilever in research into weight loss products based on the Hoodia plant used by the San people of the Kalahari Desert for centuries as an appetite suppressant is a prime example of potential problems with the current system.1 The tension that arises in this relationship is whether source communities have any claim emanating from their input in the modern drug development process.
Aman Gebru, Intellectual Property and Bioprospecting: A Model Legal Framework, 19 N.C.J.L. & Tech. 257 (2018), available at http://ncjolt.org/wp-content/uploads/2018/04/Gebru_Final.pdf.
The North Carolina Journal of Law & Technology has adopted the Open Access Program, a part of the Scholar’s Copyright Project created by Science Commons. Authors designate the conditions under which their articles are licensed. By downloading articles, you agree to comply with the license terms specified. Please contact NC JOLT at email@example.com with permissions inquiries.